| Drug Name |
Moxifloxacin |
| Drug ID |
BADD_D01501 |
| Description |
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. |
| Indications and Usage |
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye). |
| Marketing Status |
approved; investigational |
| ATC Code |
J01MA14; S01AE07 |
| DrugBank ID |
DB00218
|
| KEGG ID |
D08237
|
| MeSH ID |
D000077266
|
| PubChem ID |
152946
|
| TTD Drug ID |
D0ZV0Z
|
| NDC Product Code |
65977-0038; 51407-321; 63629-8357; 0378-5430; 65862-840; 72189-321; 16714-643; 50090-6357; 55111-112; 70518-3713; 80425-0239; 50090-5833; 53002-2723; 68180-421; 61919-553; 72789-233; 60505-0582; 68180-422; 72189-334; 17478-519; 31722-845; 0904-6406; 12527-0517; 50090-3147 |
| UNII |
U188XYD42P
|
| Synonyms |
Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039 |
